AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operations and Financial Condition.
On January9, 2017, Amicus Therapeutics,Inc. (the Company) issued
a press release (the Press Release) regarding its financial
condition for the year ended December31, 2016. A copy of the
Press Release is furnished as Exhibit99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure
Press Release
The Press Release also includes information regarding the
Companys 2016 accomplishments and its strategic outlook and
financial guidance for the year ending December31, 2017.
A copy of the Press Release is furnished as Exhibit99.1 to this
Current Report on Form8-K and is incorporated herein by
reference.
Corporate Presentation
The Company has updated its corporate presentation as of
January9, 2017. The slides from this presentation are attached
hereto as Exhibit 99.2. The attached materials will be posted on
the Companys website at www.amicusrx.com. The Company does not
undertake to update this presentation.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits:
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release dated January9, 2017 |
|
|
99.2 |
Corporate Presentation |
About AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD)
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability. AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) Recent Trading Information
AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) closed its last trading session down -0.17 at 5.61 with 4,956,522 shares trading hands.
